In a move aimed at improving operational efficiency and cutting costs, London-based Autolus Therapeutics is letting go of about 13% of employees, the company announced April 29. The biotech, which develops autologous CAR T therapies, did not identify which locations the workforce reduction will affect but noted that it will impact all areas of the business. Autolus has a U.S. presence through its Gaithersburg, Maryland, office.
While the company said it’s cutting 13% of the workforce, it also noted that the reorganization includes “employee-related actions taken beginning in the second half of 2025.” When asked to clarify that statement, a spokesperson told BioSpace in an email that some employees were let go in the second half of last year, but “the number didn’t rise to the level of ‘material’ thus there was no announcement.” Those cuts, they added, count as part of the 13%.
The spokesperson did not identify how many people were laid off in the second half of last year. Autolus had 752 employees as of Dec. 31, according to its 2025 annual report.
Autolus plans to mostly complete the latest cuts by the third quarter and to save about $15 million on an annualized basis beginning in 2027, according to the announcement. The biotech expects its current and projected cash, cash equivalents and marketable securities will fund operations into the fourth quarter of 2027. Autolus had cash and cash equivalents of $104.1 million and marketable securities of $196.6 million as of Dec. 31, according to its annual report.